Feb 16, 2026 08:01AM
Feb 2, 2026 08:00AM
Nov 18, 2025 08:00AM
Nov 12, 2025 07:01AM
Nov 10, 2025 08:00AM
Oct 28, 2025 08:03AM
Oct 28, 2025 08:00AM Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
Oct 27, 2025 08:00AM
Oct 9, 2025 07:31AM
Oct 9, 2025 07:30AM
Oct 1, 2025 06:57AM
Sep 30, 2025 07:31AM
Sep 30, 2025 07:30AM
Sep 3, 2025 07:01AM ACURX regains nasdaq compliance with bid price and equity rules
Sep 3, 2025 07:01AM
Aug 12, 2025 07:01AM
Jul 31, 2025 09:25AM
Jul 31, 2025 09:25AM
Jul 24, 2025 07:01AM
Jun 17, 2025 09:47PM
Jun 17, 2025 09:47PM /C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./
Jun 17, 2025 07:01AM
Jun 9, 2025 07:30AM
May 13, 2025 07:01AM
Apr 30, 2025 07:30AM
Apr 28, 2025 07:30AM
Apr 17, 2025 07:31AM
Apr 17, 2025 07:30AM Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
Mar 18, 2025 07:01AM
Mar 10, 2025 04:30PM
Mar 7, 2025 08:01AM
Mar 7, 2025 08:00AM
Mar 3, 2025 08:00AM
Feb 28, 2025 08:00AM
Feb 24, 2025 08:05AM Acurx Pharmaceuticals (ACXP) Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Feb 24, 2025 08:00AM
Feb 19, 2025 08:02AM
Feb 19, 2025 08:00AM
Jan 7, 2025 05:00PM
Jan 6, 2025 05:35PM
Jan 6, 2025 08:34AM
Jan 6, 2025 08:30AM Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)
Dec 11, 2024 11:00AM
Dec 9, 2024 08:02AM
Dec 9, 2024 08:00AM
Nov 20, 2024 07:01AM
Nov 20, 2024 07:01AM
Nov 18, 2024 07:00AM
Nov 13, 2024 07:00AM Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update
Oct 21, 2024 07:03AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All